The Institute for Clinical Effectiveness and Health Policy (IECS), the Pan American Health Organization (PAHO/WHO), and the USAID Bureau for Global Health's flagship maternal, neonatal and child health program, the Maternal and Child Health Integrated Program (MCHIP) made an economic evaluation of oxytocin in Uniject™ injection system versus standard use of oxytocin for the prevention of postpartum hemorrhage in the active management of the third stage of labor in Latin America and the Caribbean.
To access the full version of the report click here: Uniject Report Full
You may obtain the results of the economic evaluation of the Uniject™ injection system for each of the countries included in the study and/or modify the suggested inputs according to your criteria or personal considerations using the platform available below.
Postpartum hemorrhage (PPH) is a leading cause of maternal death. Despite strong evidence showing the efficacy of oxytocin in preventing PPH, use of the drug for this purpose remains suboptimal. The Uniject injection system prefilled with oxytocin (OiU) has the potential advantage, due to its ease of use, to increase oxytocin coverage rates (OCR).
The objective of this study is to estimate the impact of replacing oxytocin in ampoules with OiU on the incidence of PPH, quality-adjusted life years (QALYs), and costs in Latin America and the Caribbean. In order to do this, an epidemiological model that estimated the impact of this intervention on health system costs, incidence of PPH and quality-adjusted life years (QALYs) in each country was built.
The results of the economic evaluation and the technical description of the model can be found here. This web platform was built as a tool to enable decision makers and researchers in each country to gauge the economic model to their context, allowing the possibility of selecting new values for the various parameters thus obtaining results that better reflect the local reality of their country or region.
Source of funding: This project was financed through a research contract between the Institute for Clinical Effectiveness and Health Policy (IECS), the Pan American Health Organization (PAHO/WHO), and the USAID Bureau for Global Health's flagship maternal, neonatal and child health program, the Maternal and Child Health Integrated Program (MCHIP). USAID funding was made possible by the generous support of the American people through the United States Agency for International Development (USAID), under the terms of the Leader with Associates Cooperative Agreement GHS-A-00-08-00002-00. The contents are the responsibility of the IECS and MCHIP and do not necessarily reflect the views of USAID, the United States Government, or PAHO.